Ironwood Pharmaceuticals (IRWD) Q4 2025 earnings summary

Executive summary

• Achieved full year 2025 guidance with $865 million in LINZESS U.S. net sales, driven by 11% demand growth and 8% new-to-brand volume growth year-over-year.

• LINZESS received FDA approval for IBS-C in patients 7–17 years old, expanding its clinical profile.

• Ended 2025 with $215 million in cash and cash equivalents, supporting ongoing operations, 2026 growth, and deleveraging.

• Generated $24 million GAAP net income and $138 million adjusted EBITDA for 2025.

• Advanced apraglutide program with FDA alignment on Phase III trial (STARS-2); site activation expected in Q2 2026.

Financial highlights

• LINZESS net sales: $163 million in Q4 2025 (down 27% YoY), $865 million for full year (down 6% YoY), with net price erosion offset by prescription demand growth.

• Total revenue: $296 million; GAAP net income: $24 million; Adjusted EBITDA: $138 million.

• Commercial margin on LINZESS sales was 66% for FY25.

• Generated $127 million in cash flows from operations and reduced operating expenses by $61 million YoY.

• Ended 2025 with $215 million in cash and cash equivalents.

Outlook and guidance

• 2026 LINZESS U.S. net sales expected between $1.125 billion and $1.175 billion, a >30% YoY increase, driven by improved net price and low single-digit demand growth.

• Total revenue guidance for 2026: $450–$475 million; Adjusted EBITDA expected to exceed $300 million.

• Plan to reduce total debt to ~$300 million by year-end 2026, less than 1x 2026 Adjusted EBITDA.

• LINZESS list price lowered effective January 1, 2026, to support patient access and eliminate inflationary rebate components.

• No material expenses from business development activities assumed in FY26 guidance.